Cholecystokinin receptors in human pancreatic cancer cell lines

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1455-1459

  Mandair, K K ^a   Towner, P ^a   Stamford, I F ^a   Morris, J D ^a   Harper, E ^b   Benjamin, I S ^a   Tavares, I A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

Cell lines; Cholecystokinin receptors; Focal adhesion kinase; Human pancreatic cancer; K ras

Indexed keywords

CHOLECYSTOKININ RECEPTOR; FOCAL ADHESION KINASE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL GROWTH; HUMAN; HUMAN CELL; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; CELL ADHESION MOLECULES; CELL DIVISION; EXONS; FOCAL ADHESION KINASE 1; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENES, RAS; HUMANS; MICE; PANCREATIC NEOPLASMS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; TUMOR CELLS, CULTURED;

EID: 0032146280     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00143-9     Document Type: Article

References (27)

1. 1. Boring C. Cancer statistics. CA Cancer J Clin 1993, 43, 18.
2. 2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas have mutant c-K-ras genes. Cell 1988, 53, 549-554.
3. 3. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991, 64, 1076-1081.
4. 4. Caldas C, Hahn SA, Dacosta L, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994, 8, 27-32.
5. 5. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271, 350-353.
6. 6. Funakoshi A, Kono A. Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice. Gastroenterol Jpn 1992, 27, 78-82.
7. 7. Morimoto H, Nio Y, Tsubono M, et al. Inhibitory effects of a cholecystokinin antagonist, loxiglumide (CR-1505), on the growth of freshly separated and xenografted human pancreatic cancer. J Surg Oncol 1993, 53, 47-53.
8. 8. Liehr RM, Melnykoych G, Solomon T. Growth effects of regulatory peptides on human pancreatic cancer cell line PANC-1 and MIA PaCa-2. Gastroenterology 1990, 98, 1666-1674.
9. 9. Hays SE, Beinfeld MC, Jensen RT, Goodwin FK, Paul SM. Demonstration of a putative receptor site for cholecystokinin in rat brain. Neuropeptides 1980, 1, 53-62.
10. 10. Jensen RT, Lemp GR, Gardner JD. Interactions of COOH-terminal fragments of cholecystokinin with receptors on dispersed acini from guinea pig pancreas. J Biol Chem 1982, 257, 5554-5559.
11. 11. Woodruff GN, Hughes J. Cholecystokinin antagonists. Ann Rev Pharmacol Toxicol 1991, 31, 469-502.
12. 12. De Weerth A, Pisegna JR, Huppi K, Wank SA. Molecular cloning, functional expression and chromosomal localisation of the human cholecystokinin type A receptor. Biochem Biophys Res Commun 1993, 194, 811-818.
13. 13. Pisegna JR, De Weerth A, Huppi K, Wank SA. Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localisation. Biochem Biophys Res Commun 1992, 189, 296-303.
14. 14. Schaller MD, Borgman CA, Cobb BS, Vines RR, Reynolds AB, Parsons JT. pp125FAK, a structurally distinctive protein-tyrosine kinase associated with focal adhesions. PNAS 1992, 89, 5192-5196.
15. MAP. Oncogene 1994, 9, 861-867.
16. 16. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidium-thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162, 156-159.
17. 17. Rychlik W, Spencer WJ, Rhoads RE. A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA. Nucleic Acid Res 1989, 17, 8543-8551.
18. 18. Sumi S, Beauchamp RD, Townsend CM, et al. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 1994, 9, 657-661.
19. B/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol 1993, 43, 595-602.
20. 20. Lotti VL, Chang RSI. A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L365,280. Eur J Pharmacol 1989, 162, 273-280.
21. 21. Dembinski AB, Johnson LR. Stimulation of pancreatic growth by secretin, caerulein and pentagastrin. Endocrinology 1980, 106, 323-328.
22. 22. Johnson LR, Aures D, Yeun L. Pentagastrin-induced stimulation of protein synthesis in the gastrointestinal tract. Am J Physiol 1969, 217, 251-254.
23. 23. Smith JP, Kramer ST, Solomon TE. Cholecystokinin stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept 1991, 32, 341-349.
24. 24. Nio Y, Tsubono M, Morimoto H, et al. Loxiglumide (CR 1505), a cholecystokinin antagonist, specifically inhibits the growth of human pancreatic cancer cell lines xenografted into nude mice. Cancer 1993, 72, 3599-3606.
25. 25. Seva C, Kowalski-Chauvel A, Blanchet JS, Vaysse N, Pradayrol L. Gastrin induces tyrosine phosphorylation of Shc proteins and their association with the Grb2/Sos complex. FEBS Lett 1996, 378, 74-78.
26. 26. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994, 4, 82-89.
27. 27. O'Hara BM, Oskarsson M, Tainsky MA, Blair DG. Mee Mechanism of activation of human ras genes cloned from a gastric adenocarcinoma and a pancreatic carcinoma cell line. Cancer Res 1986, 46, 4695-4700.